Business
Premier Biomedical and Auramedi Farmacêutica Agree to Explore Forming Joint Venture in Brazil
Premier Biomedical and Auramedi Farmacêutica Agree to Explore Forming Joint Venture in Brazil.
About this update from Premier Biomedical Inc
[{"type":"text","content":"\n \n Premier Biomedical, Inc. (OTCQB:BIEI), \n a biotech research public company, and Auramedi Farmacêutica Ltda (a \n Brazilian pharmaceutical company) announced the signing of a non-binding \n Letter of Intent (LOI) to enter into discussions to explore forming a \n possible Joint Venture (JV) in Brazil to develop Premier’s various \n treatment technologies, and oversee the manufacture and distribution of \n the drugs and devices in the South American market initially. The \n formation of this joint venture is expected to expedite the approval, \n manufacture, sales and distribution of Premier’s proprietary treatments. \n A third party has projected annual sales, in South America, for \n Premier’s treatments at $400M by the year 2020.\n \n \n William A. Hartman, President and CEO of Premier Biomedical, stated: “We \n are very excited to embark on this relationship with such a dedicated \n pharmaceutical company as Auramedi. We expect that the resulting JV will \n be beneficial not only to Premier and Auramedi, but to the patients in \n Brazil and South America suffering from hard to cure or previously \n incurable diseases for which we are working very hard to bring effective \n treatments to market. The Joint Venture will have access to all of \n Premier’s currently available drugs and treatments, as well as those \n under development.”\n \n \n Telesforo Cáceres, Director of Auramedi Farmacêutica, \n declared: “Auramedi was designed, and created, to operate in segments \n such as Dermatology, Oncology, rare diseases and other difficult to \n treat diseases. We are very excited about the future possibilities that \n this strategic alliance with Premier Biomedical raises. The anticipated \n Joint Venture meets our goals relative to technology transfer, research \n and manufacturing of innovative products and treatments in Brazil, and \n will contribute significantly to saving lives and improving the quality \n of life for patients in our country and South America. The Joint Venture \n is expected to allow Auramedi to participate in markets that are \n estimated in Brazil at around $600 million today, and currently lacking \n therapeutic innovations.”\n \n \n About Auramedi Farmacêutica Ltda\n \n \n Auramedi (http://www.auramedi.com/) \n is a Brazilian pharmaceu...